Effect of magnesium supplementation on depression status in depressed patients with magnesium deficiency: A randomized, double-blind, placebo-controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The aim of this study was to determine the effect of magnesium supplementation on the depression status of depressed patients suffering from magnesium deficiency.

Who Took Part

The age groups tagged for this paper are young adults and adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Sixty depressed people suffering from hypomagnesemia participated in this trial.

The Beck Depression Inventory-II was conducted and the concentration of serum magnesium was measured.

What Was Measured

The subject headings attached to it are Depression, Dietary Supplements, Magnesium, Magnesium Deficiency and Psychiatric Status Rating Scales.

The authors tagged it with the keywords Magnesium supplementation and N-methyl-d-aspartate (NMDA).

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Nutrition (Burbank, Los Angeles County, Calif.)), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.